China Double Cra (600062.SS) Maintains Flat Trajectory Amid Stable Trading Conditions
China Double Cra’s share price closed unchanged at CNY 16.28 during the 24‑hour trading window that ended at 12:52 AM Central Europe on Wednesday, 21 October 2026. The absence of movement reflects a consolidation phase after a modest 1.99 % rise since the close of the previous month.
Current Market Position
| Metric | Value |
|---|---|
| Shares Outstanding | 1 billion |
| Market Capitalisation | CNY 16.9 bn |
| Volume (last 24 h) | CNY 93 mn |
| Price (current) | CNY 16.28 |
| 200‑day SMA | CNY 16.44 |
| 52‑week High | CNY 19.77 (12 Nov 2025) |
| 52‑week Low | CNY 15.29 (29 Jun 2026) |
The price sits slightly below the 200‑day moving average, signalling a neutral short‑term outlook. The 52‑week range demonstrates that the stock has recently traded nearer its low, suggesting potential room for upside if support levels hold.
Peer Comparison (Last 24 h)
| Stock | Ticker | Current Price | Market Cap (bn) | P/E |
|---|---|---|---|---|
| Giantec Semiconductor | 688123.SS | CNY 131.36 | 20.2 | 31.49 |
| Sany Renewable Energy L | 688349.SS | CNY 13.79 | 20.3 | — |
| Guangzhou Zhujiang Brewery | 002461.SZ | CNY 8.83 | 20.2 | 20.98 |
| Dhc Software | 002065.SZ | CNY 6.46 | 20.2 | 44.94 |
| Zhende Medical | 603301.SS | CNY 80 | 20.2 | 74.31 |
China Double Cra’s valuation remains modest compared with the peer set, reflecting its stable growth profile rather than speculative momentum.
Strategic Outlook
China Resources Double‑Crane Pharmaceutical Co., Ltd. (China Double Cra) continues to focus on its core pharmaceutical pipeline, including anti‑influenza, antihypertensive, and antibiotic products. The company’s long‑standing presence in the Beijing market and a strong R&D base position it well to capture incremental demand in China’s expanding healthcare sector.
With a market capitalisation of CNY 16.9 bn and a steady trading volume, the stock offers a low‑risk entry point for investors seeking exposure to the Chinese pharmaceutical landscape. The current flat trading environment presents an opportunity to assess the stock’s intrinsic value without the distortion of short‑term volatility.
Bottom line: China Double Cra’s stable performance, coupled with its robust fundamentals and favourable valuation relative to peers, signals a cautiously optimistic trajectory. Investors should monitor the stock’s adherence to the 200‑day SMA and any shifts in the 52‑week range as potential indicators of a breakout or retracement.
